News

Picture website

Scenic Biotech and the Barth Syndrome Foundation Announce Partnership to Explore Genetic Modifiers to Find Tailored Treatment for the Complex Rare Disease

1. scenic biotech genetic modifier image 1

Proof of concept in preclinical models for the use of QPCTL inhibition

Rene van den oever

Scenic Biotech Announces $31 Million Financing to Progress Pipeline of Genetic Modifiers in Cancer and Rare Diseases

Genbanner ecp green i

Biocentury features an emerging company profile on Scenic Biotech

Sebastian Nijman presenting at BioTrinity 2021

Rene van den oever

Scenic Biotech and Genentech expand their Genetic Modifier Partnership

Phillipe dro (1)

Scenic Biotech Appoints Dr. Philippe Dro as Independent Chairman

Ton Schumacher, member of Scenic’s Scientific Advisory Board has been awarded the Jeantet-Collen Prize for Translational Medicine

1. scenic biotech genetic modifier image 1

Scenic’s Chief Scientific Officer Sebastian Nijman explains why genetic modifiers are an untapped source of drug targets

Scenic Biotech Enters into Genetic Modifier Collaboration with Genentech

2. c5w4ahaxeaawkds

Scenic founders publish paper in Science Signaling

Izeboud oscar 1200

Scenic Biotech Appoints Oscar Izeboud as Chief Executive Officer